On Wednesday, shares of Clinuvel Pharmaceuticals Limited (ASX: CUV) dropped by 1.6%. The firm exchanged as small as A$ 28.30 ($20.07) and closed for the last time at A$ 28.45 ($20.18), 85,990 hands traded during trading. Previously, the stock had closed at A$ 28.90 ($20.50).
The stock has an average moving price of A$ 28.40 for 50 days and an average moving price of A$ 30.22 for two hundred days. The stock has $1.39 billion in market capitalization and a PE ratio of 77.68. The company has a 0.76 debt-to-equity ratio, 11.78 fast ratios and 12.33 current ratio.
In related news, in a transaction that took place on Monday, December 2nd, insider Philippe Wolgen 1,513,750 shares of the company’s stock.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical firm, focuses on the development of drugs to treat severe skin conditions in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for phototoxicity prevention in adult patients with erythropoietic protoporphyria that has completed Phase II and III studies in the United States and Europe.